8-K: Indivior Raises 2025 Guidance on Strong SUBLOCADE Growth

Indivior PLC reported strong Q3 2025 financial results, driven by SUBLOCADE growth and strategic business optimization, leading to raised full-year 2025 financial guidance.

Summary

• Q3 2025 Total Net Revenue was $314 million, an increase of 2% year-over-year.
• Q3 2025 SUBLOCADE Net Revenue reached $219 million, up 15% year-over-year.
• Full-year 2025 financial guidance was raised, with Total Net Revenue now expected between $1,180 million and $1,220 million (previously $1,030 million to $1,080 million).
• Full-year 2025 SUBLOCADE Net Revenue guidance was increased to $825 million to $845 million (previously $765 million to $785 million).
• Full-year 2025 Adjusted EBITDA guidance was raised to $400 million to $420 million (previously $275 million to $300 million).
• The company expects annual operating expense savings of at least $150 million in 2026 from business simplification actions.
• Strategic actions include optimizing the Rest of World (ROW) business by exiting several non-U.S. markets (U.K., Ireland, Sweden, Israel, Finland, and Italy) and discontinuing sales and marketing support for OPVEE.
• Indivior is on track to enter Phase II of its 'Indivior Action Agenda,' named 'Accelerate,' in January 2026.
• Q3 2025 GAAP Net Income was $42 million, compared to $22 million in Q3 2024.
• Cash and investments totaled $473 million at the end of Q3 2025, an increase of $125 million from the end of 2024.

Sentiment

Score: 8

Explanation: The company reported strong Q3 results, particularly for its key product SUBLOCADE, and significantly raised its full-year financial guidance. Strategic simplification efforts are expected to yield substantial cost savings and improve profitability and cash flow, indicating a positive trajectory.

Positives

• SUBLOCADE net revenue grew strongly by 15% year-over-year to $219 million in Q3 2025, with U.S. SUBLOCADE net revenue increasing 14% to $203 million.
• Full-year 2025 financial guidance was significantly raised across total net revenue, SUBLOCADE net revenue, and adjusted EBITDA, reflecting stronger performance.
• Expected annual operating expense savings of at least $150 million beginning in 2026 due to organizational simplification.
• SUBOXONE Film experienced price stability in the U.S. generic buprenorphine/naloxone sublingual film market.
• GAAP net income for Q3 2025 increased 95% to $42 million, and non-GAAP diluted EPS rose to $0.72 from $0.49 in Q3 2024.
• Adjusted EBITDA increased 14% to $120 million in Q3 2025, demonstrating positive operating leverage.
• The company maintains a strong cash position with $473 million in cash and investments and an adjusted leverage ratio of less than 1.0x.
• Launched a national direct-to-consumer (DTC) campaign, 'Move Forward in Recovery,' to support SUBLOCADE growth.
• Expanded U.S. indexation with inclusion in the MSCI U.S. Indices and the S&P Total Market Index.
• Published positive clinical trial results in JAMA Network Open for rapid SUBLOCADE induction, showing higher treatment retention rates.

Negatives

• GAAP gross margin in Q3 2025 was 73%, a decrease from 79% in Q3 2024, although non-GAAP gross margin improved.
• SUBOXONE Film revenue declined due to generic competition, despite some price stabilization.
• OPVEE volumes decreased, and marketing and promotion for PERSERIS were discontinued in July 2024.
• The optimization of the Rest of World (ROW) business involves exiting several non-U.S. markets, indicating a reduced global presence.
• Ongoing generic erosion of the legacy SUBUTEX (buprenorphine) tablet business in ROW markets.

Risks

• Future sales of products may be lower than expected.
• Impacts from competition could be greater than anticipated.
• Unanticipated costs, including the effects of potential tariffs and retaliatory tariffs, may arise.
• The company may not be able to identify efficiencies and fund additional investments to generate increased revenues, or the timing of such actions may be delayed.
• Failure to obtain necessary court and shareholder approval to change the company's domicile to the U.S. could occur.
• Results of pending and future clinical trials may not be favorable.
• Decisions of relevant regulators may not be favorable.
• Market acceptance of long-acting injectables may be lower than expected.

Future Outlook

Indivior expects year-over-year total net revenue growth in 2025, with adjusted EBITDA projected to increase 15% year-over-year at the mid-point of its revised guidance ranges. The company is on track to enter Phase II of its 'Indivior Action Agenda,' called 'Accelerate,' in January 2026, which is anticipated to deliver immediate accretion to adjusted EBITDA and improved cash generation. Phase III, 'Breakout,' is planned for H2 2026 and beyond, focusing on leveraging a strengthened financial profile to acquire new growth drivers. Healthcare professionals anticipate long-acting injectable (LAI) usage in the buprenorphine medication assisted treatment (BMAT) population to increase significantly from current levels to 20-30%. The Phase II clinical trials for INDV-2000 and INDV-6001 are estimated to complete their Last Patient Last Visit in Q4 2025.

Management Comments

• Joe Ciaffoni, CEO: "In the third quarter, we executed on Phase I of the Indivior Action Agenda, Generate Momentum, by growing SUBLOCADE and simplifying the business."
• Joe Ciaffoni, CEO: "Commercial execution drove strong SUBLOCADE performance in the quarter, and we established our go-forward operating model that is expected to generate at least $150 million in annual operating expense savings beginning in 2026."
• Joe Ciaffoni, CEO: "We are on track to move into Phase II of the Indivior Action Agenda, Accelerate, and expect to deliver immediate accretion to the bottom line and improved cash generation beginning in January 2026."
• Ryan Preblick, CFO: "Strong SUBLOCADE net revenue growth and SUBOXONE Film price stability in the U.S. led us to raise our 2025 financial guidance."
• Ryan Preblick, CFO: "We now expect year-over-year total net revenue growth in 2025, with adjusted EBITDA expected to increase 15% year-over-year at the mid-point of our guidance ranges."
• Ryan Preblick, CFO: "The actions Indivior has taken to simplify the organization, including reducing headcount, consolidating our footprint, discontinuing commercial support of OPVEE, optimizing the ROW business and plans to redomicile in the U.S., are expected to generate immediate accretion to adjusted EBITDA in 2026."

Industry Context

Indivior operates within the critical and growing market of opioid use disorder (OUD) treatment, which remains a significant public health crisis in the U.S. The company's flagship product, SUBLOCADE, a long-acting injectable (LAI) buprenorphine, is positioned to capitalize on the increasing demand for effective OUD treatments, especially given the proliferation of high-potency synthetic opioids like fentanyl. The LAI segment of buprenorphine medication assisted treatment (BMAT) is currently under-penetrated at approximately 8% usage, but healthcare professionals anticipate this could grow to 20-30%, indicating substantial market potential. The ongoing bipartisan support for addressing the opioid crisis, including legislative acts and renewed public health emergency declarations, provides a favorable environment for companies like Indivior focused on evidence-based OUD therapies.

Comparison to Industry Standards

• SUBLOCADE is highlighted as the No. 1 prescribed long-acting injectable (LAI) in the U.S. for opioid use disorder (OUD), having treated over 435,000 patients.
• It is the only once-monthly LAI that allows for rapid initiation on Day 1, a key differentiator in the OUD treatment landscape.
• SUBLOCADE is designed to deliver stable buprenorphine plasma levels, maintaining concentrations above 2 ng/mL throughout the dosing interval after the second injection, which is considered optimal for controlling OUD symptoms, cravings, and blocking opioid-rewarding effects.
• The filing implicitly compares SUBLOCADE to other LAI buprenorphine products like BRIXADI (Braeburn Inc.) and VIVITROL (Alkermes, Inc.) by referencing their prescribing information for half-life data, emphasizing SUBLOCADE's continuous, long-lasting protection with a 43 to 60-day half-life.

Corporate Governance

Legal Proceedings

• Accrued current litigation settlement expenses were $106 million as of September 30, 2025, compared to $99 million at the end of 2024.
• Accrued non-current litigation settlement expenses were $300 million as of September 30, 2025, compared to $365 million at the end of 2024.
• An HMRC settlement, relating to aspects of prior years' intercompany financing arrangements, became probable during the second quarter of 2025; this settlement is not expected to impact future tax rates.

Stakeholder Impact

• Shareholders are positively impacted by significantly raised financial guidance, expected substantial operating expense savings, increased profitability, strong cash generation, and strategic moves to enhance U.S. capital markets presence.
• Employees in R&D and Medical Affairs organizations may be negatively impacted by restructuring, including facility closures and headcount reductions.
• Customers (patients with OUD) are positively impacted by continued investment in SUBLOCADE, including a new direct-to-consumer campaign, and positive clinical trial results aimed at improving treatment access and outcomes.
• Suppliers related to the Rest of World (ROW) markets being exited and the OPVEE product may experience negative impacts.
• Creditors benefit from the company's strong balance sheet, with $473 million in cash and investments and an adjusted leverage ratio of less than 1.0x, indicating robust financial health and capacity to meet obligations.

Next Steps

• Enter Phase II of the Indivior Action Agenda, 'Accelerate,' on January 1, 2026, focusing on accelerating U.S. SUBLOCADE net revenue and generating immediate accretion from profitability and cash flow growth.
• Pursue the intention to change the company's domicile from the U.K. to the U.S. and establish a new U.S. parent company, Indivior Pharmaceuticals, Inc.
• Continue to invest at sustained levels in the 'Move Forward in Recovery' direct-to-consumer (DTC) campaign for SUBLOCADE.
• Complete Last Patient Last Visit for INDV-6001 and INDV-2000 Phase II clinical trials in Q4 2025.
• Begin Phase III of the Indivior Action Agenda, 'Breakout,' in H2 2026 and beyond, aiming to leverage a strengthened financial profile to acquire next growth drivers.

Key Dates

Recommendation

Indivior delivered robust Q3 2025 results, significantly exceeding prior expectations and leading to a substantial upward revision of its full-year 2025 financial guidance across key metrics like total net revenue, SUBLOCADE net revenue, and adjusted EBITDA. The strategic 'Indivior Action Agenda' is demonstrating tangible benefits, with SUBLOCADE showing strong growth and simplification efforts projected to generate at least $150 million in annual operating expense savings starting in 2026. The planned redomiciliation to the U.S. and increased U.S. indexation are positive for capital markets presence. With a strong balance sheet, significant cash flow generation, and a clear strategic path focused on its core growth driver in a high-need market, the company is well-positioned for continued profitability and value creation.

Keywords

Opioid Use Disorder, SUBLOCADE, Buprenorphine, Long-acting injectable, Pharmaceuticals, Financial results, Guidance raise, Corporate restructuring, Addiction treatment, Healthcare, Biotechnology